Colorectal cancer (CRC) is one of the most common and deadliest forms of cancer worldwide. Molecular subgroups are increasingly relevant for prognosis and therapy. In addition to established markers such as RAS, BRAF and MSI, HER2 is also coming into focus as a therapeutic target. Particularly rare histological variants such as invasive micropapillary carcinoma (IMPC) raise new questions. A recent case report from Japan describes for the first time a patient with HER2-positive colorectal carcinoma and a micropapillary component. This article summarizes the available data and discusses the clinical significance of this constellation.
Autoren
- Tanja Schliebe
Publikation
- InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
You May Also Like
- Proteins in wound healing
Do special amino acids lead to success?
- Case study
Autosomal recessive polycystic kidney disease: atypical phenotype
- Current evidence, risk classes and new counseling options
Hormonal contraception and cardiovascular risk
- Acute otitis media: self-limiting course vs. "red flags"
In which cases are antibiotics necessary?
- Prurigo nodularis: evidence-based treatment
Targeted therapy options on the rise
- MACE risk, heart failure incidence and all-cause mortality
Metabolic syndrome as a cardiovascular risk factor
- Glaucoma in old age: slowing down progression
IOP lowering is currently the only evidence-based treatment
- Vector-borne infections with skin manifestations